MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Arrowhead Pharmaceuticals EPS Ratio 2011-2026 | ARWR
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -5 | -1.92 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 | -1.34 | -1.6 | -1.25 | -1.3 | -1.9 | -0.44 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.72 | -5 | -1.27 |
Quarterly EPS Ratio Arrowhead Pharmaceuticals
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.26 | -1.39 | - | -1.38 | -1.02 | -1.24 | - | -0.96 | 0.46 | -0.39 | - | -0.68 | 0.42 | -0.6 | - | -0.29 | -0.26 | -0.2 | -0.48 | -0.13 | -0.2 | -0.03 | 0.12 | 0.21 | -0.03 | 0.13 | -0.12 | -0.18 | 0.13 | -0.18 | -0.14 | -0.07 | -0.18 | -0.17 | -0.34 | -0.32 | -0.17 | -0.32 | -0.42 | -0.27 | -0.32 | -0.41 | -0.42 | -0.22 | -0.41 | -0.28 | -0.43 | -0.23 | -0.41 | -0.33 | -1.48 | -0.71 | -0.5 | -0.25 | -0.05 | -0.25 | 0.4 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.46 | -1.48 | -0.344 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Adagene
ADAG
|
-0.59 | $ 2.83 | -2.75 % | $ 159 M |  China |
 |
Biogen
BIIB
|
11.2 | $ 177.27 | 0.62 % | $ 25.8 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
-1.04 | $ 81.19 | -0.98 % | $ 1.57 B | USA |
 |
Amgen
AMGN
|
7.62 | $ 339.82 | -0.91 % | $ 182 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
BioNTech SE
BNTX
|
42.2 | $ 114.47 | -1.97 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
75.3 | $ 9.65 | -0.16 % | $ 1.52 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | Britain |
 |
Aytu BioScience
AYTU
|
-2.16 | $ 2.56 | -0.78 % | $ 16.1 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.23 | -0.92 % | $ 7.77 B |  Australia |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
CASI Pharmaceuticals
CASI
|
-0.27 | $ 0.99 | - | $ 135 M | USA |
 |
Catalyst Biosciences
CBIO
|
-1.41 | $ 10.0 | -1.43 % | $ 658 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
Cerus Corporation
CERS
|
-0.11 | $ 2.3 | -1.08 % | $ 424 M | USA |
 |
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Cellectis S.A.
CLLS
|
-2.55 | $ 3.81 | -4.51 % | $ 116 M | France |
 |
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Beam Therapeutics
BEAM
|
-4.58 | $ 28.26 | -3.52 % | $ 2.33 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-8.28 | $ 223.79 | -0.07 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
1.38 | $ 24.53 | -0.2 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
-0.95 | $ 1.68 | 3.75 % | $ 80.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-0.81 | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-0.09 | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
-1.42 | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 4.03 | -1.71 % | $ 8.77 B |  Israel |
 |
Amneal Pharmaceuticals
AMRX
|
-0.38 | $ 13.77 | -2.45 % | $ 4.25 B | USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-2.08 | - | -74.18 % | $ 955 K | USA |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |